Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

45.34USD
17 Aug 2017
Change (% chg)

$-0.60 (-1.30%)
Prev Close
$45.94
Open
$45.46
Day's High
$45.82
Day's Low
$45.31
Volume
2,352,582
Avg. Vol
2,007,449
52-wk High
$47.98
52-wk Low
$30.89

Select another date:
Photo

Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

(This version of the story corrects paragraph 8 to remove reference to absorption of insulin)

CORRECTED-UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

CORRECTED-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

BRIEF-Novo Nordisk says Semaglutide superior to Dulaglutide in sustain 7 trial

* Novo nordisk says semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in sustain 7

BRIEF-‍Metacrine enters collaboration with Novo Nordisk to develop FGF 1 variants for glucose lowering, insulin sensitization​

* ‍Metacrine - entered collaboration with Novo Nordisk A/S to develop fibroblast growth factor 1 variants for glucose lowering and insulin sensitization​

UPDATE 2-Novo Nordisk raises forecasts despite continued U.S. pressure

* Shares jump more than 6 percent (Adds management comments, obesity drugs background, shares)

BRIEF-Novo Nordisk CEO says won't provide explicit guidance on price

* CEO SAYS NOVO NORDISK DO NOT INTEND TO PROVIDE EXPLICIT GUIDANCE ON PRICE IN THE FUTURE

NORDIC STOCKS - Factors to watch on August 9

OSLO, Aug 9 The following stocks may be affected by newspaper reports and other factors on Wednesday:

Novo Nordisk Q2 beats forecast; lifts outlook but sees lower U.S. prices in 2018

COPENHAGEN, Aug 9 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, posted second-quarter operating profit above forecasts, but said prices in its key U.S. market after rebates would be lower next year.

Select another date: